Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Avouac

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Clinical and Experimental Rheumatology|January 29, 2011
Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysisAnouck Rémy, Jerome Avouac, Laure Gossec, et al.
Disease Markers|May 29, 2018
Soluble CD163 as a Potential Biomarker in Systemic SclerosisCamelia Frantz, Sonia Pezet, Jerome Avouac, et al.
Frontiers in Immunology|October 31, 2018
Regulatory T Cells in Systemic SclerosisCamelia Frantz, Cedric Auffray, Jerome Avouac, et al.
Seminars in Arthritis and Rheumatism|July 5, 2011
Spleen calcifications in connective tissue disordersJosep A Farras, Jerome Avouac, Marine Meunier, et al.
The Journal of Rheumatology|September 10, 2009
Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agentsEugenie Koumakis, Julien Wipff, Jerome Avouac, et al.
The Journal of Rheumatology|September 17, 2010
High DNA oxidative damage in systemic sclerosisJerome Avouac, Didier Borderie, Ovanesse Garabed Ekindjian, et al.
Clinical and Experimental Rheumatology|February 24, 2017
Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteriaSerge Perrot, Mariana Peixoto, Philippe Dieudé, et al.
RMD Open|February 8, 2023
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung diseaseOmar Al Tabaa, Roba Ghossan, Alice Combier, et al.
Journal of Clinical Medicine|April 18, 2019
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target StrategyPeter C Taylor, Alejandro Balsa Criado, Anne-Barbara Mongey, et al.
Arthritis Research & Therapy|November 14, 2023
Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosisNadira Ruzehaji, Jerome Avouac, Muriel Elhai, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Clinical and Experimental Rheumatology|January 29, 2011
Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysisAnouck Rémy, Jerome Avouac, Laure Gossec, et al.
Disease Markers|May 29, 2018
Soluble CD163 as a Potential Biomarker in Systemic SclerosisCamelia Frantz, Sonia Pezet, Jerome Avouac, et al.
Frontiers in Immunology|October 31, 2018
Regulatory T Cells in Systemic SclerosisCamelia Frantz, Cedric Auffray, Jerome Avouac, et al.
Seminars in Arthritis and Rheumatism|July 5, 2011
Spleen calcifications in connective tissue disordersJosep A Farras, Jerome Avouac, Marine Meunier, et al.
The Journal of Rheumatology|September 10, 2009
Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agentsEugenie Koumakis, Julien Wipff, Jerome Avouac, et al.
The Journal of Rheumatology|September 17, 2010
High DNA oxidative damage in systemic sclerosisJerome Avouac, Didier Borderie, Ovanesse Garabed Ekindjian, et al.
Clinical and Experimental Rheumatology|February 24, 2017
Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteriaSerge Perrot, Mariana Peixoto, Philippe Dieudé, et al.
RMD Open|February 8, 2023
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung diseaseOmar Al Tabaa, Roba Ghossan, Alice Combier, et al.
Journal of Clinical Medicine|April 18, 2019
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target StrategyPeter C Taylor, Alejandro Balsa Criado, Anne-Barbara Mongey, et al.
Arthritis Research & Therapy|November 14, 2023
Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosisNadira Ruzehaji, Jerome Avouac, Muriel Elhai, et al.
Pageof 6